glp-1 pediatric receptor agonists in obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety pediatric GLP‑1 treatment - Diabetes

Commercial Insurance: Tightening Coverage Many Plans Dropping or Restricting Coverage (Jan 2026) Effective January 1, 2026, multiple insurers have dropped or restricted GLP-1 coverage for weight loss , limiting it to type 2 diabetes or plans with explicit weight management benefits: [11] Health New England: Dropped Wegovy, Zepbound, and Saxenda coverage for individual and small group members effective January 1, 2026 Fallon Health: Community Care plans no longer cover weight loss medications as of January 1, 2026 BCBS, UnitedHealthcare, Cigna: Many plans restricting GLP-1s to type 2 diabetes only, unless employers opt for weight management riders CVS Caremark: Removed Zepbound from standard formulary effective July 1, 2025

In 90 patients with acute-on-chronic hepatitis B infections, Wang et al

Cosmetics 5.3.9

Sbaraglini ML, Molinuevo MS, Sedlinsky C, Schurman L, McCarthy AD

Then United States Chamber of Commerce lobbyist William Kovacs said that Kennedy's nomination "would speak volumes as to where Obama is going with his appointments